Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 1
2021 3
2022 10
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Yano S, Kawaoka T, Yamasaki S, Johira Y, Kosaka M, Shirane Y, Miura R, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Miki D, Tsuge M, Teraoka Y, Kouno H, Takaki S, Mori N, Tsuji K, Oka S. Yano S, et al. Among authors: miura r. Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406. Cancers (Basel). 2023. PMID: 38001666 Free PMC article.
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Aikata H. Ando Y, et al. Among authors: miura r. Liver Cancer. 2022 Nov 29;12(3):251-261. doi: 10.1159/000528145. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37601981 Free PMC article.
Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets.
Fujita M, Chen MM, Siwak DR, Sasagawa S, Oosawa-Tatsuguchi A, Arihiro K, Ono A, Miura R, Maejima K, Aikata H, Ueno M, Hayami S, Yamaue H, Chayama K, Lee JS, Lu Y, Mills GB, Liang H, Nishizuka SS, Nakagawa H. Fujita M, et al. Among authors: miura r. Nat Commun. 2022 Oct 29;13(1):6481. doi: 10.1038/s41467-022-34249-x. Nat Commun. 2022. PMID: 36309506 Free PMC article.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Murakami S, Yano S, Naruto K, Ando Y, Kosaka Y, Fujii Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Moriya T, Naeshiro N, Nonaka M, Hyogo H, Aisaka Y, Azakami T, Hiramatsu A, Aikata H. Amioka K, et al. Among authors: miura r. Cancers (Basel). 2022 Jan 10;14(2):320. doi: 10.3390/cancers14020320. Cancers (Basel). 2022. PMID: 35053484 Free PMC article.
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Kosaka Y, Kawaoka T, Kosaka M, Shirane Y, Miura R, Murakami S, Johira Y, Yano S, Amioka K, Naruto K, Ando Y, Kodama K, Uchikawa S, Fujino H, Ohno A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Aikata H. Kosaka Y, et al. Among authors: miura r. Intern Med. 2023 Jun 15;62(12):1771-1774. doi: 10.2169/internalmedicine.9581-22. Epub 2022 Nov 2. Intern Med. 2023. PMID: 36328580 Free PMC article.
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Johira Y, Kawaoka T, Kosaka M, Shirane Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Ando Y, Kosaka Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Sentani K, Oue N, Arihiro K, Kuroda S, Kobayashi T, Ohdan H, Chayama K, Aikata H. Johira Y, et al. Among authors: miura r. Liver Cancer. 2021 Nov 15;11(2):174-177. doi: 10.1159/000520898. eCollection 2022 Apr. Liver Cancer. 2021. PMID: 35634428 Free PMC article. No abstract available.
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
Kodama K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Yano S, Murakami S, Amioka K, Naruto K, Ando Y, Kosaka Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Miki D, Imamura M, Kuroda S, Kobayashi T, Ohdan H, Aikata H, Chayama K. Kodama K, et al. Among authors: miura r. J Gastroenterol. 2022 Sep;57(9):676-683. doi: 10.1007/s00535-022-01887-3. Epub 2022 Jul 18. J Gastroenterol. 2022. PMID: 35849192
The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
Zhang P, Ono A, Fujii Y, Hayes CN, Tamura Y, Miura R, Shirane Y, Nakahara H, Yamauchi M, Uchikawa S, Uchida T, Teraoka Y, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Okamoto W, Makokha GN, Imamura M, Arihiro K, Kobayashi T, Ohdan H, Fujita M, Nakagawa H, Chayama K, Aikata H. Zhang P, et al. Among authors: miura r. Int J Cancer. 2022 Dec 15;151(12):2278-2290. doi: 10.1002/ijc.34247. Epub 2022 Sep 2. Int J Cancer. 2022. PMID: 36054900 Free article.
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Miura R, Kawaoka T, Imamura M, Kosaka M, Johira Y, Shirane Y, Murakami S, Yano S, Amioka K, Naruto K, Ando Y, Kosaka Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Hinoi T, Aikata H. Miura R, et al. Case Rep Gastroenterol. 2022 Mar 4;16(1):110-115. doi: 10.1159/000522145. eCollection 2022 Jan-Apr. Case Rep Gastroenterol. 2022. PMID: 35431768 Free PMC article.
19 results